In this episode of Emerging Experts, Paolo Tarantino, MD, discusses groundbreaking advancements in breast cancer research, focusing on HER2-low subtypes and the role of antibody-drug conjugates in modern oncology. Discover the challenges in patient selection for ADCs, the impact of social media on research dissemination, and what the future holds for HER2-targeted therapies. Harvard Medical School, Dana-Farber Cancer Institute LISTEN NOW: https://lnkd.in/eh2firMd OR Watch the full discussion on our YouTube channel: https://lnkd.in/ekMNYbRV
Targeted Oncology
Online Audio and Video Media
Cranbury Township, New Jersey 53,123 followers
The Community Resource in Targeted Therapies
About us
TargetedOnc.com provides content focused on next generation therapeutics and their molecular targets. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying recent and up-to-date with the future of cancer therapeutics. TargetedOnc.com focuses on the next stage of cancer development, focusing on cutting edge therapies and their biological targets. Content is organized by therapy type, target, peer-reviewed content, and conference coverage.
- Website
-
http://targetedonc.com
External link for Targeted Oncology
- Industry
- Online Audio and Video Media
- Company size
- 2-10 employees
- Headquarters
- Cranbury Township, New Jersey
- Type
- Public Company
- Specialties
- Oncology, Healthcare Communications, Healthcare, Cancer Research, Targeted Therapies, Community Oncology, Cancer, Cancer Treatment, and Oncologists
Locations
-
Primary
2 Clarke Dr
Cranbury Township, New Jersey, US
Employees at Targeted Oncology
Updates
-
The #FDA granted NXP800 orphan drug designation for the potential treatment of patients with ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. #GYNCSM https://lnkd.in/eeTkKhwg
-
WATCH: Kenneth Shain, MD, PhD, discusses the rationale for giving CAR T-cell therapy in earlier lines of therapy for relapsed/refractory multiple myeloma. #MMSM | Moffitt Cancer Center https://lnkd.in/eyf3EZnJ
Efficacy and Treatment-Free Interval Support Earlier Use of CAR T in R/R Myeloma
targetedonc.com
-
ICYMI: The FDA has accepted the supplemental biologics license application for nivolumab + ipilimumab in the first line for patients with unresectable hepatocellular carcinoma. https://lnkd.in/eeaeR4kN
-
-
In this series, Jamie L. Koprivnikar, MD, discusses a case of a 70-year-old man with SF3B1+ #MDS with ring sideroblasts and discusses the approach to initial therapy in patients with lower-risk MDS who may have moderate-to-severe anemia. WATCH NOW: https://lnkd.in/e2atPgb9 Hackensack Meridian Health
Approach to 1L Therapy Selection in LR-MDS
targetedonc.com
-
Knowledge in molecular diagnostics and cancer research is driving a new era in cancer care—precision oncology—where interventions and treatments are tailored to each patient’s disease characteristics. The US Oncology Network https://lnkd.in/eywFhZ5h
Technology Drives Biomarker Testing Rates in Precision Oncology
targetedonc.com
-
Balancing access and safety in CAR T-cell therapy 🌟 Discover how monitoring practices and REMS updates are evolving and what it means for institutions in this exclusive interview with William Wesson, MD, of The University of Kansas Cancer Center. #CAR-T https://lnkd.in/e4sNSVVF
-
-
The first patient with advanced #NSCLC with a tumor that has activating HER2 mutations has been enrolled in the phase 3 SOHO-02 trial of frontline treatment with BAY 2927088. Bayer | Pharmaceuticals https://lnkd.in/ef5CFTJt
Enrollment Begins in Phase 3 SOHO-02 Trial of BAY 2927088 in NSCLC
targetedonc.com
-
Targeted Oncology reposted this
ADCs are ideally meant to selectively deliver a chemotherapy into tumor cells. But how precise is the current generation of ADCs? What other layers of activity do they harbor, in addition to antibody-directed homing of the payload? Thanks to Targeted Oncology for this interview
In this episode of Emerging Experts, Paolo Tarantino, MD, discusses groundbreaking advancements in breast cancer research, focusing on HER2-low subtypes and the role of antibody-drug conjugates in modern oncology. Discover the challenges in patient selection for ADCs, the impact of social media on research dissemination, and what the future holds for HER2-targeted therapies. Harvard Medical School, Dana-Farber Cancer Institute LISTEN NOW: https://lnkd.in/eh2firMd OR Watch the full discussion on our YouTube channel: https://lnkd.in/ekMNYbRV
-
The first patient has been dosed in the phase 3 HIGHLIGHT 1 trial of fezolinetant for the potential treatment of patients with moderate to severe vasomotor symptoms with breast cancer receiving adjuvant endocrine therapy. #BCSM | Astellas Pharma https://lnkd.in/eYEHunJS
Fezolinetant Trial for Hot Flashes in Patients With HR+ Breast Cancer Starts Enrollment
targetedonc.com